High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
高通量筛选化合物以减轻 FUS/TLS 的毒性
基本信息
- 批准号:8348533
- 负责人:
- 金额:$ 53.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAge-MonthsAmyotrophic Lateral SclerosisAttenuatedBehavioralBiological AssayBrainCause of DeathCell NucleusCell modelCellsCuprozinc Superoxide DismutaseCytoplasmCytosolDataDefectDiseaseDrosophila genusDrug KineticsFamilial Amyotrophic Lateral SclerosisGene ExpressionGenesGeneticGliosisGoalsHumanHuman Cell LineIn VitroInflammationInheritedInvestigationLeadLethal Dose 50LinkLocationMammalian CellMediatingMessenger RNAMetabolicModelingMotorMotor NeuronsMovementMusMutateMutationNerveNerve DegenerationNeurodegenerative DisordersNeuronsParalysedPathologyPatientsPharmaceutical ChemistryPharmaceutical PreparationsPreclinical Drug EvaluationPrionsProcessProteinsRNARNA-Binding Protein FUSScreening procedureSeriesSpinal CordStructure-Activity RelationshipTestingTherapeutic EffectTherapeutic InterventionToxic effectTransgenesTransgenic MiceTransgenic OrganismsValidationVariantWild Type MouseYeast Model SystemYeastscytotoxicityexperiencegene discoveryhigh throughput screeninghuman diseasein vivoinnovationkillingsliposarcomamembermotor neuron degenerationmouse modelmutantphysical propertyprogramspromoterprotein expressionresearch studysarcomasmall moleculestable cell linesuperoxide dismutase 1therapy development
项目摘要
DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is an untreatable, paralytic neurodegenerative disorder that is uniformly lethal, usually within 3-5 years. Members of our team have identified mutations in two genes whose mutations cause dominantly inherited familial ALS (fALS): Cu,Zn superoxide dismutase-1 (SOD1), the first identified ALS gene, and FUS/TLS. Respectively, these account for 20% and 5% of fALS cases. Presently, it is not clear how mutant SOD1 or mutant FUS cause fALS; it is likely that the former involves instability of the mutant SOD1 protein and aberrant protein processing, while the latter implicates perturbations of RNA function, as indicated in part by the observation that mutant FUS is often mislocalized to the cytosol. The goal of this proposed project is to discover small molecules that inhibit the cytotoxicity of mutant forms of SOD1 and FUS/TLS. Our hypotheses are that (1) factors that re-direct FUS from the cytoplasm to the nucleus will attenuate FUS- mediated toxicity in ALS patients; and (2) a reduction in the load of toxic mutant-SOD1 proteins will have a
therapeutic effect in ALS patients. We have substantial data documenting that our screening and validation assays are functional and thus are confident that our high-throughput screening has the potential to identify small molecules and genetic factors that ameliorate toxicity of mutant forms of both FUS and SOD1. Our study has four aims. Aim 1 is to conduct high throughput screening for compounds that mitigate toxicity of mutant FUS and SOD1 using a yeast model of FUS toxicity (Aim 1A), an HEK293 cell model of FUS mislocalization (Aim 1B) and an HEK model of quantifiable SOD1 expression (Aim 1C). The deliverable from Aim 1 is at least five compounds with efficacy at levels <5 ¿M and toxicity at levels >25 ¿M. Aim 2 is to validate hits from Aim 1, using Drosophila and primary neuronal models of FUS toxicity (Aim 2A) and human cell lines for analysis of SOD1 gene expression. Aim 3 is to optimize the lead compound series and establish structure-activity relationships. The deliverable from Aims 2 and 3 are three compounds from each of the two screening platforms (six total) with efficacy a <1 ¿M and LD50 >50 ¿M that will then be tested in FUS and ALS transgenic mice. Aim 4 is to conduct trials of the six best validated compounds in the transgenic FUS and SOD1G93A mice (three compounds in each). These studies will address two questions. First, do the compound hits achieve anticipated target effects in vivo (for FUS: reduction of FUS-mediated pathology; for SOD1: reduction of SOD1 mRNA and protein levels) (Aim 4A)? And, do the hits ameliorate motor or behavioral abnormalities or prolong survival? (Aim 4B). In our view, this program entails a high degree of innovation both in the assays employed and in the pilot set of compounds discovered so far. We also believe that these investigations hold considerable significance; the need for any meaningful therapeutic intervention in ALS is compelling. Moreover, it is conceivable that the compounds discovered in these studies will prove beneficial in neurodegenerative conditions other than ALS alone.
PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis (ALS) is an untreatable disease that kills motor nerves (which control movement) and causes death in humans within 3-5 years. Our proposed project will focus on two genetic causes of ALS: mutations (or gene defects) in both Cu,Zn superoxide dismutase-1 (SOD1) and Fused in sarcoma/Translocated in liposarcoma (FUS/TLS or FUS). Mutations in these genes account for 25 30% of inherited ALS cases. While we do not fully understand how mutations in SOD1 or FUS cause ALS, we know that reducing the amount of mutant-SOD1 in motor neurons protects these cells from dying, and that the location of FUS in the cell correlates with its toxicity. Normally FUS is concentrated in the nucleus. However mutated FUS is concentrated in the cytoplasm, which surrounds the nucleus. We propose high-through put screens for drug-like molecules that can reduce levels of SOD1 and reduce the toxicity of FUS, possibly by restoring FUS to the nucleus. These drug-like molecules may therefore lead to new treatments for ALS patients.
描述(申请人提供):肌萎缩侧索硬化症(ALS)是一种无法治疗的麻痹性神经退行性疾病,通常在3-5年内致死。我们团队的成员已经确定了两个基因的突变,其突变导致显性遗传性家族性ALS(fALS):Cu,Zn超氧化物歧化酶-1(SOD 1),第一个确定的ALS基因,和FUS/TLS。分别占fALS病例的20%和5%。目前,还不清楚突变体SOD 1或突变体FUS如何引起fALS;很可能前者涉及突变体SOD 1蛋白的不稳定性和异常蛋白质加工,而后者涉及RNA功能的扰动,如突变体FUS经常错误定位于细胞质的观察所示。该项目的目标是发现抑制SOD 1和FUS/TLS突变形式细胞毒性的小分子。我们的假设是:(1)将FUS从细胞质重定向到细胞核的因素将减弱ALS患者中FUS介导的毒性;(2)毒性MUSC-SOD 1蛋白负荷的减少将使ALS患者中FUS介导的毒性降低。
ALS患者的治疗效果。我们有大量的数据证明我们的筛选和验证试验是有效的,因此我们相信我们的高通量筛选有可能鉴定出改善FUS和SOD 1突变形式毒性的小分子和遗传因子。我们的研究有四个目标。目的1是使用FUS毒性的酵母模型(Aim 1A)、FUS错误定位的HEK 293细胞模型(Aim 1B)和可定量的SOD 1表达的HEK模型(Aim 1C)对减轻突变FUS和SOD 1毒性的化合物进行高通量筛选。目标1的可交付成果是至少五种化合物,其效力水平<5 μ M,毒性水平>25 μ M。目的2是使用果蝇和FUS毒性的原代神经元模型(目的2A)和人细胞系分析SOD 1基因表达,验证目的1的命中。目的3:优化先导化合物系列,建立构效关系。目标2和3的可交付物是来自两个筛选平台(总共六个)中的每一个的三种化合物,其功效<1 μ M且LD 50>50 μ M,然后将在FUS和ALS转基因小鼠中进行测试。目的4是在转基因FUS和SOD 1G 93 A小鼠中进行六种最佳验证化合物的试验(每种三种化合物)。这些研究将解决两个问题。首先,化合物命中是否在体内达到预期的靶效应(对于FUS:减少FUS介导的病理学;对于SOD 1:降低SOD 1 mRNA和蛋白质水平)(目的4A)?而且,这些打击是否改善了运动或行为异常或延长了生存期?(Aim 4B)。在我们看来,这一计划需要高度的创新,无论是在所采用的测定和迄今发现的化合物的试点集。我们还认为,这些研究具有相当大的意义;对ALS进行任何有意义的治疗干预的必要性是迫切的。此外,可以想象的是,在这些研究中发现的化合物将证明在除了单独的ALS之外的神经退行性疾病中有益。
公共卫生关系:肌萎缩侧索硬化症(ALS)是一种无法治愈的疾病,它会杀死运动神经(控制运动),并在3-5年内导致人类死亡。我们提出的项目将集中在ALS的两个遗传原因:突变(或基因缺陷)在铜,锌超氧化物歧化酶-1(SOD 1)和融合在肉瘤/易位在脂肪肉瘤(FUS/TLS或FUS)。这些基因的突变占遗传性ALS病例的25 - 30%。虽然我们还不完全了解SOD 1或FUS的突变是如何导致ALS的,但我们知道减少运动神经元中的MUD-SOD 1的数量可以保护这些细胞免于死亡,并且FUS在细胞中的位置与其毒性相关。通常FUS集中在细胞核中。然而,突变的FUS集中在细胞质中,其围绕细胞核。我们提出了高通量筛选药物样分子,可以降低SOD 1的水平,降低FUS的毒性,可能是通过将FUS恢复到细胞核。因此,这些药物样分子可能为ALS患者带来新的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert H. Brown其他文献
Site of functional bronchopulmonary anastomoses in sheep
绵羊功能性支气管肺吻合部位
- DOI:
10.1002/(sici)1097-0185(19990301)254:3<360::aid-ar6>3.0.co;2-4 - 发表时间:
1999 - 期刊:
- 影响因子:0
- 作者:
E. Wagner;W. Mitzner;Robert H. Brown - 通讯作者:
Robert H. Brown
Putting the heat on ALS
加大 ALS 力度
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:0
- 作者:
Susanna C. Benn;Robert H. Brown - 通讯作者:
Robert H. Brown
A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain
Xtampza ER 治疗中重度慢性腰痛患者的一项 3 期、多中心、随机、双盲、安慰剂对照、安全性、耐受性和疗效研究
- DOI:
- 发表时间:
2015 - 期刊:
- 影响因子:7.4
- 作者:
Nathaniel Katz;E. Kopecky;Melinda OʼConnor;Robert H. Brown;A. Fleming - 通讯作者:
A. Fleming
Infrared Images of Jupiter at 5-Micrometer Wavelength During the Voyager 1 Encounter
航海者 1 号遭遇木星时的 5 微米波长红外图像
- DOI:
- 发表时间:
1979 - 期刊:
- 影响因子:56.9
- 作者:
R. Terrile;R. Capps;D. Backman;E. Becklin;Dale P. Cruikshank;C. Beichman;Robert H. Brown;J. Westphal - 通讯作者:
J. Westphal
HRCT Imaging of Airway Responsiveness: Effects of Anesthetics
气道反应性的 HRCT 成像:麻醉药的影响
- DOI:
10.1023/a:1011496810978 - 发表时间:
2004 - 期刊:
- 影响因子:2.2
- 作者:
Robert H. Brown - 通讯作者:
Robert H. Brown
Robert H. Brown的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert H. Brown', 18)}}的其他基金
Next-generation antisense therapeutics for ALS and frontotemporal dementia
针对 ALS 和额颞叶痴呆的下一代反义疗法
- 批准号:
10599901 - 财政年份:2019
- 资助金额:
$ 53.91万 - 项目类别:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
针对 ALS 和额颞叶痴呆的下一代反义疗法
- 批准号:
9765950 - 财政年份:2019
- 资助金额:
$ 53.91万 - 项目类别:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
针对 ALS 和额颞叶痴呆的下一代反义疗法
- 批准号:
10374767 - 财政年份:2019
- 资助金额:
$ 53.91万 - 项目类别:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
针对 ALS 和额颞叶痴呆的下一代反义疗法
- 批准号:
9924676 - 财政年份:2019
- 资助金额:
$ 53.91万 - 项目类别:
Silencing C9or72 with rAAV Mediated RNAi
用 rAAV 介导的 RNAi 沉默 C9or72
- 批准号:
8767751 - 财政年份:2014
- 资助金额:
$ 53.91万 - 项目类别:
Silencing C9or72 with rAAV Mediated RNAi
用 rAAV 介导的 RNAi 沉默 C9or72
- 批准号:
9042441 - 财政年份:2014
- 资助金额:
$ 53.91万 - 项目类别:
Silencing C9or72 with rAAV Mediated RNAi
用 rAAV 介导的 RNAi 沉默 C9or72
- 批准号:
8853963 - 财政年份:2014
- 资助金额:
$ 53.91万 - 项目类别:
Silencing C9or72 with rAAV Mediated RNAi
用 rAAV 介导的 RNAi 沉默 C9or72
- 批准号:
9267549 - 财政年份:2014
- 资助金额:
$ 53.91万 - 项目类别:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
高通量筛选化合物以减轻 FUS/TLS 的毒性
- 批准号:
8500486 - 财政年份:2012
- 资助金额:
$ 53.91万 - 项目类别:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
高通量筛选化合物以减轻 FUS/TLS 的毒性
- 批准号:
8640222 - 财政年份:2012
- 资助金额:
$ 53.91万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 53.91万 - 项目类别:
Research Grant